At first blush, the $66 million Series B round that startup FogPharma is announcing this morning seems standard fare, particularly this year, when private biotechs have raised gobs of cash hand over fist. But a closer look shows careful steps by an academic-turned-executive, Greg Verdine, to develop the type of company he wants. He’s amassed an unusual array of hand-picked investors who, he says, will largely let him maintain control of his company.
FogPharma is developing an unproven, new class of medicines called “cell-penetrating mini-proteins,” which combine attributes of small molecules and biologics, to try to get at drug targets… Read more »
UNDERWRITERS AND PARTNERS